How is Edwards Lifesciences (EW) doing?

Edwards Lifesciences is a company in the medical, devices industry, based in Irvine, CA, worth $49.1B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Middling

Edwards Lifesciences shares are up 13% over the past year, 3 points behind the S&P 500. Its type is Hot Hand. Among large US stocks and funds it ranks in the 59th percentile on market beat, the 8th on staying power and the 90th on business growth. It appears on 5 of our dashboards, including 3rd on “Which companies are built to last?”.

$85.21+13% in a yearWorth $49.1B

Compare with MDT · ABT · BSX · SYK · BDX

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

EW against the S&P 500, past year

$100 a year ago. Edwards Lifesciences +13%, the S&P 500 +16%.

EWS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Hot Hand

BeatingErraticGrowingBought

Beating the market on a growing business with buyers adding, but its rank swings from week to week.

NovDecJanFebMarAprMayJunJulAugSepNow

Hot Hand this month; Coiled Spring before that.

Also Hot Hand (59 in all): DXCM · GMED · HALO · LH · NVST · ABBV

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

EW, past year+13%50 of 86 in the group

Rest of the group+21%equal-weighted

S&P 500+16%past year

Edwards Lifesciences is +13% over the past year, against +21% for the rest of the group and +16% for the S&P 500. It ranks 50th of 86 in Health care.

EWRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsMDT Medtronic−10%ABT Abbott Laboratories−26%BSX Boston Scientific−56%SYK Stryker−26%BDX Becton Dickinson+21%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Edwards Lifesciences typically moves 2.5% in a day, about usual for it, and it swings less than 71% of large US stocks.

Typical day2.5%about $2.17 a share

Its usual2.6%about usual, 1.0× its year’s average

Against the S&P 5002.3×the index’s typical day is 1.1%

Unusual day±5.1%twice its typical day

Deepest fall, past year−13%now 10% below its high

In the S&P’s down weeks100%of the index’s fall, three years; beta 0.7

Typical daily move (ATR)Its year’s average 2.57%

EW on our dashboards

Every question where Edwards Lifesciences appears, in the order of the home page, with its reading and place in that table. Select a question to open it with EW highlighted. Select a column to sort.

Question	Reading	Place	Details
Which businesses are getting better? Business quality	90Improving	50 of 60	Revenue growth +14% · Cash-flow growth +67% · Operating margin 28%
Which companies are built to last? Business quality	81Durable	3 of 60	Steady margins 92 · Reliable cash 57 · Balance sheet 95
Which companies invest the most in research? Business quality	78Moderate	44 of 60	R&D / revenue 16.7% · R&D a year $1.1B · R&D, 1Y +3%
Which companies have more cash than debt? Value	96Net cash	16 of 60	Net cash $3.0B · % of value +6% · Debt payback 0.6 yrs
What are insiders buying? Who’s buying and selling	83Selling	13 of 60	Sold $53K · Who Cvp, TAVR

Go deeper on Stox

EW’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open EW on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see EW’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›MDT · Medtronic ›ABT · Abbott Laboratories ›BSX · Boston Scientific ›SYK · Stryker ›